Serum Markers of T-Cell Activation in Relapses of Wegener’s Granulomatosis

  • C. A. Stegeman
  • J. W. Cohen Tervaert
  • M. G. Huitema
  • C. G. M. Kallenberg
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 336)

Summary

Levels of soluble IL-2 receptor (sIL-2R), soluble CD4 (sCD4) and CD8 (sCD8) were measured by sandwich ELISA as markers for T-cell activation in serial serum samples drawn monthly from 16 patients showing 18 histologically proven relapses of Wegener’s granulomatosis (WG). Levels of sIL-2R increased from 1162 U/ml (median, 95% CI 843 to 1814 U/ml) at three months before the relapse to 1684 U/ml (95% CI 1254 to 2202 U/ml) at the time of relapse for the whole group (P = 0.10). The 8 major relapses showed a profound rise in sIL-2R levels (P < 0.01). The level of sIL-2R at the moment of relapse correlated with the level of C-reactive protein (r = 0.547, P < 0.05) and with the disease activity score (r = 0.814, P < 0.001). There were no significant changes in levels of sCD4 or sCD8.

Keywords

Disease Activity Score Serum sCD4 Serial Serum Sample Minor Relapse Major Relapse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Borg ter EJ, Horst G, Limburg PC, Kallenberg CGM, 1990, Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus. Clin Exp Immunol. 82, 21–27.PubMedCrossRefGoogle Scholar
  2. Brouwer E, Cohen Tervaert JW, Weening JJ, Kallenberg CGM, 1991, Immunohistopathology of renal biopsies in Wegener’s granulomatosis (WG): clues to it’s pathogenesis? Kidney Int. 39, 1055–1056.Google Scholar
  3. Cohen Tervaert JW, Woude van der FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF, Meijer S, Giessen van der M, The TH, Hem van der GK, Kallenberg CGM. (1989) Association between active Wegener’s Granulomatosis and anticytoplasmic antibodies. Arch Intern Med. 149, 2461–2465.Google Scholar
  4. Cohen Tervaert JW, Huitema MG, Hené RJ, Sluiter WJ, The TH, Hem van der GK, Kallenberg CGM. (1990) Relapses of Wegener’s granulomatosis: prevention by treatment based on antineutrophil cytoplasmic antibody levels–a controlled prospective study -. Lancet 336, 709–711.Google Scholar
  5. Fauci AS, Haynes BF, Katz P. (1978) The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med. 89, 660–676.PubMedCrossRefGoogle Scholar
  6. Kallenberg CGM, Cohen Tervaert JW, Stegeman CA. (1990) Criteria for disease activity in Wegener’s granulomatosis: a requirement for longitudinal clinical studies. APMIS. 98, 37–40.Google Scholar
  7. Manoussakis MN, Papadopoulos GK, Drosos AA, Moutsopoulos HM. (1989) Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases. Clin Immunol Immunopathol. 50, 321–332.PubMedCrossRefGoogle Scholar
  8. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL. (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 135, 3172–3177.PubMedGoogle Scholar
  9. Woude van der FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, Es van LA, Giessen van der M, Hem van der GK, The TH. (1985) Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1, 425–428.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • C. A. Stegeman
    • 1
    • 2
  • J. W. Cohen Tervaert
    • 1
    • 2
  • M. G. Huitema
    • 2
  • C. G. M. Kallenberg
    • 2
  1. 1.Department of NephrologyUniversity Hospital GroningenGroningenThe Netherlands
  2. 2.Clinical ImmunologyUniversity Hospital GroningenGroningenThe Netherlands

Personalised recommendations